Nevro Corp. has announced the launch of HFX Connect in Europe and CE marking of expanded labelling (Painful Diabetic Neuropathy, PDN and Non-Surgical Back Pain, NSBP) for the HFX SCS system. The latest development from the global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, enables increased healthcare system efficiencies, patient access to remote optimisation, and unique labelling for outcomes beyond pain relief.

HFX Connect will be available to both new Omnia? patients and those already implanted, allowing healthcare teams to remotely optimize patients with 35 pre-programmed customisable treatment plans, and seven times the amount originally available. In addition, the latest regulatory approval includes expanded labelling for HFX.

HFX is now the world's first and only SCS therapy with approved CE mark for pain relief and sensory improvement in PDN patients. The latest specific labelling is for all major SCS indications, including Back &Leg pain, Non-Surgical Back Pain, Painful Diabetic Neuropathy and Upper Limb and Neck pain. Furthermore, the labelling now includes expected clinical benefits beyond pain relief.

The market release of HFX Connect in Europe follows commercial launch in the USA and Australia.